KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Cash: 2009-2024

Historic Change in Cash for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to -$2.5 million.

  • Halozyme Therapeutics' Change in Cash rose 1166.61% to $357.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.3 million, marking a year-over-year increase of 321.29%. This contributed to the annual value of -$2.5 million for FY2024, which is 97.83% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Change in Cash stood at -$2.5 million for FY2024, which was up 97.83% from -$116.3 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Change in Cash ranged from a high of $115.5 million in FY2022 and a low of -$116.3 million during FY2023.
  • Moreover, its 3-year median value for Change in Cash was -$2.5 million (2024), whereas its average is -$1.1 million.
  • In the last 5 years, Halozyme Therapeutics' Change in Cash crashed by 205.30% in 2021 and then surged by 498.41% in 2022.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Change in Cash stood at $27.5 million in 2020, then crashed by 205.30% to -$29.0 million in 2021, then spiked by 498.41% to $115.5 million in 2022, then slumped by 200.74% to -$116.3 million in 2023, then skyrocketed by 97.83% to -$2.5 million in 2024.